Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), recently received the approval notification of marketing application for chemical API Gadoterate Meglumine issued by NMPA (Notification No. 2024YS00506).
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as "Anhui Poly"), a subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as "Poly Pharm."), has recently received the Notice of Approval about application for marketing of cyclophosphamide chemical raw material issued by the National Medicinal Product Administration (hereinafter referred to as "NMPA") (Notice number: 2024YS00429).
Anhui Poly Pharm. Co., Ltd., a wholly-owned subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as "Poly Pharm." or the "Company"), recently receives First Adequate Letter (FAL)for Gadoterate Meglumine API from the US Food and Drug Administration (hereinafter referred to as "FDA").
Recently, Anhui Poly Pharm. Co., Ltd. and the School of Chemistry and Chemical Engineering, Anqing Normal University sign a graduate employment base cooperation agreement.
Recently, according to "Regulation of Anhui Enterprise Technology Center Identification" (JXKJ.AH. [2023] 24) and "Notice on Submission and Evaluation of Anhui Enterprise Technology Center " requirements, after the enterprise submission, the initial examination and joint recommendation by the municipal bureau of economic and information, development and reform, science and technology, finance, taxation and customs departments; preliminary evaluation, expert evaluation, comprehensive evaluation, public announcement and other procedures, determined that Anhui Poly and other 263 enterprise technology centers as the Anhui Enterprise Technology Center in 2023 (32nd batch), and announced the list: